Switching Regimen in Treating Cirrhotic HCV GT1b Subjects
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized study to evaluate the efficacy and safety of switching
treatment from Peg-interferon and Ribavirin to direct-acting antiviral agents in Chinese with
CHC genotype 1b infection, who are interferon/ribavirin-intolerant.
Phase:
Phase 2
Details
Lead Sponsor:
Humanity & Healthy GI and Liver Centre Humanity and Health Research Centre
Collaborators:
Beijing 302 Hospital Nanfang Hospital of Southern Medical University
Treatments:
Interferon-alpha Interferons Ledipasvir, sofosbuvir drug combination Peginterferon alfa-2a Ribavirin Simeprevir